- Home
- FSM vs SUPN Comparison
FSM vs SUPN Comparison
Compare FSM & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FSM
- SUPN
- Stock Information
- Founded
- FSM 1990
- SUPN 2005
- Country
- FSM Canada
- SUPN United States
- Employees
- FSM N/A
- SUPN N/A
- Industry
- FSM Precious Metals
- SUPN Biotechnology: Pharmaceutical Preparations
- Sector
- FSM Basic Materials
- SUPN Health Care
- Exchange
- FSM Nasdaq
- SUPN Nasdaq
- Market Cap
- FSM 2.8B
- SUPN 2.6B
- IPO Year
- FSM N/A
- SUPN 2012
- Fundamental
- Price
- FSM $7.84
- SUPN $57.00
- Analyst Decision
- FSM Hold
- SUPN Strong Buy
- Analyst Count
- FSM 1
- SUPN 4
- Target Price
- FSM $10.50
- SUPN $63.25
- AVG Volume (30 Days)
- FSM 15.2M
- SUPN 878.4K
- Earning Date
- FSM 11-05-2025
- SUPN 11-04-2025
- Dividend Yield
- FSM N/A
- SUPN N/A
- EPS Growth
- FSM 7355.92
- SUPN 1411.53
- EPS
- FSM 0.50
- SUPN 1.14
- Revenue
- FSM $1,187,211,000.00
- SUPN $665,125,000.00
- Revenue This Year
- FSM N/A
- SUPN $8.29
- Revenue Next Year
- FSM $9.78
- SUPN $22.72
- P/E Ratio
- FSM $15.70
- SUPN $49.80
- Revenue Growth
- FSM 46.81
- SUPN 5.55
- 52 Week Low
- FSM $4.13
- SUPN $29.16
- 52 Week High
- FSM $9.82
- SUPN $57.65
- Technical
- Relative Strength Index (RSI)
- FSM 41.02
- SUPN 75.83
- Support Level
- FSM $7.70
- SUPN $54.21
- Resistance Level
- FSM $8.33
- SUPN $57.65
- Average True Range (ATR)
- FSM 0.36
- SUPN 1.93
- MACD
- FSM -0.09
- SUPN 0.36
- Stochastic Oscillator
- FSM 9.00
- SUPN 87.79
About FSM Fortuna Silver Mines Inc (Canada)
Fortuna Mining Corp is a Canadian-based precious metals mining company with mines in the Latin America and West Africa regions producing gold and silver. It operate mines in Argentina, Burkina Faso, Cote d'Ivoire, Mexico, and Peru. The company's segment consists of Mansfield, Sanu, Sango, Cuzcatlan, Bateas, Corporate. The company generates the majority of its revenue from Sango segment which operates the Seguela gold mine. Geographically, the company generates the majority of its revenue from Cote d'Ivoire location.
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.